0
Observation |

Multifocal Paraneoplastic Cortical Encephalitis Associated With Myasthenia Gravis and ThymomaParaneoplastic Encephalitis With MG and Thymoma FREE

Khaled Hammoud, MD; Geetha Kandimala, MD; Worthy Warnack, MD; Steven Vernino, MD, PhD
[+] Author Affiliations

Copyright 2009 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

More Author Information
Arch Neurol. 2009;66(11):1407-1409. doi:10.1001/archneurol.2009.235
Text Size: A A A
Published online

Objectives  To report a case of multifocal cortical encephalitis associated with thymoma and to establish an association of this thymoma-related paraneoplastic syndrome with voltage-gated potassium channel antibodies.

Design  Case report.

Setting  University hospital.

Patient  A 43-year-old woman with a history of seropositive myasthenia gravis and successfully treated invasive thymoma. Four years after thymectomy, she presented with seizure and rapidly progressive confusion and aphasia. Myasthenia gravis remained in pharmacological remission. Magnetic resonance imaging of the brain showed innumerable cortically based signal abnormalities as well as extensive left mesial temporal lobe abnormality with minimal enhancement.

Results  Chest computed tomography showed abnormal pleural thickening of the left lung, which proved to be recurrent metastatic thymoma. Results of serological evaluation were positive for acetylcholine receptor, striational, and voltage-gated potassium channel antibodies. She showed partial improvement in response to immunotherapy and chemotherapy but ultimately died 2 months later of tumor complications.

Conclusions  Thymoma and myasthenia gravis may be associated with other autoimmune neurological disorders including paraneoplastic encephalitis. This second case of thymoma-associated multifocal cortical encephalitis demonstrates that autoimmune encephalitis can extend to cortical regions outside the limbic system. Autoimmune encephalitis should be considered in the differential diagnosis of patients with myasthenia gravis or thymoma who develop new cognitive symptoms.

Figures in this Article

A 43-year-old right-handed woman had a history of seropositive myasthenia gravis (MG) and invasive thymoma (stage IV) diagnosed in 2002. Her initial symptoms were fatigable weakness, dysarthria, diplopia, and ptosis. At that time, she underwent thymectomy followed by radiation therapy. She was treated with 500 mg of mycophenolate mofetil twice a day, and her symptoms improved. Myasthenia gravis was considered to be in pharmacological remission. Four years after thymectomy, she had a single unexplained seizure and started taking phenytoin. Six months after the seizure, she began complaining of intermittent nausea and vomiting and then, over a period of 1 week, she became confused and progressed rapidly to complete mutism. She presented to a local hospital. Cerebrospinal fluid analysis showed lymphocytic pleocytosis (70 cells) and elevated protein level (101 mg/dL) with a normal glucose level. Treatment with acyclovir was initiated, but she did not improve. Results of cerebrospinal fluid cultures and polymerase chain reaction analysis for herpes simplex virus and West Nile virus were negative.

She was transferred to our institution for further management. On presentation, she was awake and alert but did not speak. She appeared to be in no distress and was afebrile. She could not follow spoken commands but would attend to sounds. She would imitate gestures and could participate in the neurological examination. Strength and tendon reflexes were normal. There was no ocular or bulbar weakness; she was judged to be globally aphasic rather than anarthric. Magnetic resonance imaging of the brain showed innumerable cortically based signal abnormalities as well as extensive left mesial temporal lobe abnormality with minimal enhancement (Figure 1). Results of additional laboratory work were normal or negative, including erythrocyte sedimentation rate, antinuclear antibody titer, angiotensin-converting enzyme test, and serological tests for Lyme disease, syphilis, human immunodeficiency virus, fungi, toxoplasmosis, and West Nile virus. The complete blood cell count and CD4 T-cell count were normal. Thyroid function was normal, and results of a thyroperoxidase antibody test were negative.

Place holder to copy figure label and caption
Figure 1.

Magnetic resonance and computed tomographic images. A-D, Axial fluid-attenuated inversion recovery images showed numerous cortically based signal abnormalities. There was extensive involvement of the left mesial temporal lobe (C) (arrow) and complete sparing of the cerebellum (D). E and F, Coronal T1-weighted images after administration of gadolinium showed minimal enhancement of the left mesial temporal lobe (E) (arrow) and the large left parietal lesion (F) (arrow). The rest of the cortical lesions showed no contrast enhancement. G, Contrast-enhanced computed tomography of the chest showed abnormal pleural thickening (arrow) of the posterior left lung base consistent with metastatic thymoma.

Grahic Jump Location

Electroencephalogram showed intermittent periodic lateralized epileptiform discharges in the left temporal region as well as electrographic seizures that appeared to arise independently from both temporal lobes. Serological studies were positive for markers of MG including acetylcholine receptor binding antibody (1.45 nmol/L), acetylcholine receptor modulating antibody (100%), and striational antibodies (1:15360). Voltage-gated potassium channel antibodies were also detected (0.45 nmol/L, normal <0.02 nmol/L). The rest of the paraneoplastic antibody profile was negative, including collapsin response-mediator protein 5 antibodies.

Computed tomography of the chest with contrast was performed to assess for malignancy. This showed bands of abnormal pleural thickening at the left lung base consistent with metastatic thymoma (Figure 1G). A computed tomography–guided pleural biopsy showed a mixture of mature lymphocytes and epithelial components consistent with type B2 thymoma (Figure 2).

Place holder to copy figure label and caption
Figure 2.

Computed tomography–guided pleural biopsy showing a mixture of mature lymphocytes (small blue cells) and epithelial components (larger, pale cells) consistent with type B2 thymoma (hematoxylin-eosin, original magnification ×100).

Grahic Jump Location

She received treatment with anticonvulsants, high-dose intravenous methylprednisone (1 g daily for 5 days), and intravenous immunoglobulin (2 g/kg divided over another 5 days). She was then transferred to a cancer center, where she received 1 cycle of chemotherapy. There was some improvement of cognitive function and speech returned, but she ultimately died 2 months later of medical complications of her chest malignancy.

Thymoma is frequently associated with autoimmune disorders. About 15% of patients with MG have thymoma.1 Thymoma and MG may be associated with other autoimmune neurological disorders including paraneoplastic encephalitis.1 3 Our patient had evidence of a multifocal cortical encephalitis as well as typical radiographic features of paraneoplastic limbic encephalitis involving the left mesial temporal lobe. Her most prominent presenting symptom of severe global aphasia corresponds anatomically to involvement of the dominant frontal and temporal cortex, which was significantly involved on the magnetic resonance images and electroencephalography. This encephalitic presentation occurred in the absence of any clinical signs of worsening MG. Investigation confirmed recurrent invasive thymoma. She responded partially to intravenous immunoglobulin and chemotherapy.

There are a few previous reports of thymoma-associated paraneoplastic encephalitis with variable responses to immunomodulatory treatment.4 7 This case further establishes that autoimmune encephalitis can occur as a paraneoplastic consequence of thymoma. Most examples of paraneoplastic encephalitis involve the limbic system and related structures. To our knowledge, this is only the second case with a unique pattern of multifocal cortical involvement associated with thymoma. Potassium channel antibodies were found in this case while collapsin response-mediator protein 5 antibodies were found in the previously reported case.8 The previously reported case showed a good response to plasma exchange after other therapies failed.

Antibodies against voltage-gated potassium channels have clearly been associated with thymoma and with paraneoplastic and autoimmune forms of limbic encephalitis.9 10 These antibodies have also been associated with autonomic disturbances affecting gastrointestinal motility.11 12 All of our patient's symptoms (nausea and vomiting, seizures and encephalitis) fit within the voltage-gated potassium channel antibody clinical spectrum. Other autoantibodies typical of paraneoplastic limbic encephalitis in the context of small-cell lung carcinoma, such as antineuronal nuclear autoantibody type 1, were not found. Acetylcholine receptor binding and modulating antibodies and striational antibodies were also detected in this patient to support the diagnosis of paraneoplastic autoimmunity in the setting of thymoma.

This case emphasizes the importance of considering paraneoplastic encephalitis associated with thymoma in the differential diagnosis of patients with MG who develop new cognitive symptoms. It also emphasizes the importance of investigating for recurrent malignancy in a patient with a known history of cancer who develops new neurological symptoms. Antibody markers can help confirm the suspicion of a paraneoplastic cause and direct the search for cancer. The role of intravenous immunoglobulin or other immunomodulatory treatments in thymoma-associated encephalitis needs further evaluation.

Correspondence: Steven Vernino, MD, PhD, Department of Neurology, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-9036 (steven.vernino@utsouthwestern.edu).

Accepted for Publication: May 5, 2009.

Author Contributions:Study concept and design: Hammoud, Kandimala, Warnack, and Vernino. Acquisition of data: Hammoud, Kandimala, Warnack, and Vernino. Analysis and interpretation of data: Hammoud and Vernino. Drafting of the manuscript: Hammoud, Kandimala, Warnack, and Vernino. Critical revision of the manuscript for important intellectual content: Hammoud and Vernino. Study supervision: Vernino.

Financial Disclosure: None reported.

Additional Contributions: Vanda Lennon, MD, PhD, and the Mayo Clinic Neuroimmunology laboratory performed the serological testing for voltage-gated potassium channel antibodies and other neuronal autoantibodies.

Rosenow  EC  III, Hurley  BT. Disorders of the thymus: a review. Arch Intern Med 1984;144 (4) 763- 770
PubMed
Vernino  S, Lennon  VA. Autoantibody profiles and neurological correlations of thymoma. Clin Cancer Res 2004;10 (21) 7270- 7275
PubMed
Cunningham  JD, Burt  ME. Limbic encephalitis secondary to malignant thymoma. Ann Thorac Surg 1994;58 (1) 250- 251
PubMed
Chaudhry  MS, Waters  M, Gilligan  D. Paraneoplastic limbic encephalitis attributable to thymoma. J Thorac Oncol 2007;2 (9) 879- 880
PubMed
Monstad  SE, Nostbakken  JK, Vedeler  CA. CRMP5 antibodies found in a patient with limbic encephalitis and myasthenia gravis. J Neurol Neurosurg Psychiatry 2009;80 (2) 241- 242
PubMed
Khella  SL, Souyah  N, Dalmau  J. Thymoma, myasthenia gravis, encephalitis, and a novel anticytoplasmic neuronal antibody. Neurology 2007;69 (12) 1302- 1303
PubMed
Fujii  N, Furuta  A, Yamaguchi  H, Nakanishi  K, Iwaki  T. Limbic encephalitis associated with recurrent thymoma: a postmortem study. Neurology 2001;57 (2) 344- 347
PubMed
Rickman  OB, Parisi  JE, Yu  Z, Lennon  VA, Vernino  S. Fulminant autoimmune cortical encephalitis associated with thymoma treated with plasma exchange. Mayo Clin Proc 2000;75 (12) 1321- 1326
PubMed
Thieben  MJ, Lennon  VA, Boeve  BF, Aksamit  AJ, Keegan  M, Vernino  S. Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology 2004;62 (7) 1177- 1182
PubMed
Jarius  S, Hoffmann  LA, Stich  O.  et al.  Relative frequency of VGKC and ‘classical’ paraneoplastic antibodies in patients with limbic encephalitis. J Neurol 2008;255 (7) 1100- 1101
PubMed
Törnblom  H, Lang  B, Clover  L, Knowles  CH, Vincent  A, Lindberg  G. Autoantibodies in patients with gut motility disorders and enteric neuropathy. Scand J Gastroenterol 2007;42 (11) 1289- 1293
PubMed
Viallard  J-F, Vincent  A, Moreau  J-F, Parrens  M, Pellegrin  J-L, Ellie  E. Thymoma-associated neuromyotonia with antibodies against voltage-gated potassium channels presenting as chronic intestinal pseudo-obstruction. Eur Neurol 2005;53 (2) 60- 63
PubMed

First Page Preview

First page PDF preview

Figures

Place holder to copy figure label and caption
Figure 1.

Magnetic resonance and computed tomographic images. A-D, Axial fluid-attenuated inversion recovery images showed numerous cortically based signal abnormalities. There was extensive involvement of the left mesial temporal lobe (C) (arrow) and complete sparing of the cerebellum (D). E and F, Coronal T1-weighted images after administration of gadolinium showed minimal enhancement of the left mesial temporal lobe (E) (arrow) and the large left parietal lesion (F) (arrow). The rest of the cortical lesions showed no contrast enhancement. G, Contrast-enhanced computed tomography of the chest showed abnormal pleural thickening (arrow) of the posterior left lung base consistent with metastatic thymoma.

Grahic Jump Location
Place holder to copy figure label and caption
Figure 2.

Computed tomography–guided pleural biopsy showing a mixture of mature lymphocytes (small blue cells) and epithelial components (larger, pale cells) consistent with type B2 thymoma (hematoxylin-eosin, original magnification ×100).

Grahic Jump Location

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

Rosenow  EC  III, Hurley  BT. Disorders of the thymus: a review. Arch Intern Med 1984;144 (4) 763- 770
PubMed
Vernino  S, Lennon  VA. Autoantibody profiles and neurological correlations of thymoma. Clin Cancer Res 2004;10 (21) 7270- 7275
PubMed
Cunningham  JD, Burt  ME. Limbic encephalitis secondary to malignant thymoma. Ann Thorac Surg 1994;58 (1) 250- 251
PubMed
Chaudhry  MS, Waters  M, Gilligan  D. Paraneoplastic limbic encephalitis attributable to thymoma. J Thorac Oncol 2007;2 (9) 879- 880
PubMed
Monstad  SE, Nostbakken  JK, Vedeler  CA. CRMP5 antibodies found in a patient with limbic encephalitis and myasthenia gravis. J Neurol Neurosurg Psychiatry 2009;80 (2) 241- 242
PubMed
Khella  SL, Souyah  N, Dalmau  J. Thymoma, myasthenia gravis, encephalitis, and a novel anticytoplasmic neuronal antibody. Neurology 2007;69 (12) 1302- 1303
PubMed
Fujii  N, Furuta  A, Yamaguchi  H, Nakanishi  K, Iwaki  T. Limbic encephalitis associated with recurrent thymoma: a postmortem study. Neurology 2001;57 (2) 344- 347
PubMed
Rickman  OB, Parisi  JE, Yu  Z, Lennon  VA, Vernino  S. Fulminant autoimmune cortical encephalitis associated with thymoma treated with plasma exchange. Mayo Clin Proc 2000;75 (12) 1321- 1326
PubMed
Thieben  MJ, Lennon  VA, Boeve  BF, Aksamit  AJ, Keegan  M, Vernino  S. Potentially reversible autoimmune limbic encephalitis with neuronal potassium channel antibody. Neurology 2004;62 (7) 1177- 1182
PubMed
Jarius  S, Hoffmann  LA, Stich  O.  et al.  Relative frequency of VGKC and ‘classical’ paraneoplastic antibodies in patients with limbic encephalitis. J Neurol 2008;255 (7) 1100- 1101
PubMed
Törnblom  H, Lang  B, Clover  L, Knowles  CH, Vincent  A, Lindberg  G. Autoantibodies in patients with gut motility disorders and enteric neuropathy. Scand J Gastroenterol 2007;42 (11) 1289- 1293
PubMed
Viallard  J-F, Vincent  A, Moreau  J-F, Parrens  M, Pellegrin  J-L, Ellie  E. Thymoma-associated neuromyotonia with antibodies against voltage-gated potassium channels presenting as chronic intestinal pseudo-obstruction. Eur Neurol 2005;53 (2) 60- 63
PubMed

Correspondence

CME Course for:


You need to register in order to view this quiz.


To understand the clinical management of acute heart failure syndromes.
Accreditation Information The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
To view and print your certificate and access a summary of your CME courses go to My CME.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Topics
PubMed Articles